Warning: The NCBI web site requires JavaScript to function. more...
In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.
Savarino A.
Retrovirology. 2007 Mar 20;4:21.
Related citations
Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A, Stillmock KA, Hazuda DJ, Reznikoff WS.
Biochemistry. 2007 Sep 25;46(38):10776-89. Epub 2007 Aug 29.
Probing HIV-1 integrase inhibitor binding sites with position-specific integrase-DNA cross-linking assays.
Johnson AA, Marchand C, Patil SS, Costi R, Di Santo R, Burke TR Jr, Pommier Y.
Mol Pharmacol. 2007 Mar;71(3):893-901. Epub 2006 Dec 15.
Binding mode prediction of strand transfer HIV-1 integrase inhibitors using Tn5 transposase as a plausible surrogate model for HIV-1 integrase.
Barreca ML, De Luca L, Iraci N, Chimirri A.
J Med Chem. 2006 Jun 29;49(13):3994-7.
Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design.
Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, Davies DR.
Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13040-3.
Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode.
Barreca ML, Ortuso F, Iraci N, De Luca L, Alcaro S, Chimirri A.
Biochem Biophys Res Commun. 2007 Nov 23;363(3):554-60. Epub 2007 Sep 14.
Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS.
Savarino A, Pistello M, D'Ostilio D, Zabogli E, Taglia F, Mancini F, Ferro S, Matteucci D, De Luca L, Barreca ML, Ciervo A, Chimirri A, Ciccozzi M, Bendinelli M.
Retrovirology. 2007 Oct 30;4:79.
Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors.
Barreca ML, Iraci N, De Luca L, Chimirri A.
ChemMedChem. 2009 Sep;4(9):1446-56.
Effect of DNA modifications on DNA processing by HIV-1 integrase and inhibitor binding: role of DNA backbone flexibility and an open catalytic site.
Johnson AA, Sayer JM, Yagi H, Patil SS, Debart F, Maier MA, Corey DR, Vasseur JJ, Burke TR Jr, Marquez VE, Jerina DM, Pommier Y.
J Biol Chem. 2006 Oct 27;281(43):32428-38. Epub 2006 Aug 30.
Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF.
AIDS Rev. 2009 Jan-Mar;11(1):17-29. Review.
New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action.
Ferro S, De Luca L, Barreca ML, De Grazia S, Christ F, Debyser Z, Chimirri A.
Bioorg Med Chem. 2010 Aug 1;18(15):5510-8. Epub 2010 Jun 22.
Novel HIV integrase inhibitors with anti-HIV activity: insights into integrase inhibition from docking studies.
Cox AG, Nair V.
Antivir Chem Chemother. 2006;17(6):343-53.
Structural determinants for HIV-1 integrase inhibition by beta-diketo acids.
Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR Jr, Pommier Y.
J Biol Chem. 2002 Apr 12;277(15):12596-603. Epub 2002 Jan 22.
Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions.
Maurin C, Bailly F, Cotelle P.
Curr Med Chem. 2003 Sep;10(18):1795-810. Review.
Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site.
Wielens J, Headey SJ, Jeevarajah D, Rhodes DI, Deadman J, Chalmers DK, Scanlon MJ, Parker MW.
FEBS Lett. 2010 Apr 16;584(8):1455-62. Epub 2010 Mar 16.
HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase.
Espeseth AS, Felock P, Wolfe A, Witmer M, Grobler J, Anthony N, Egbertson M, Melamed JY, Young S, Hamill T, Cole JL, Hazuda DJ.
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11244-9.
Prediction of HIV-1 integrase/viral DNA interactions in the catalytic domain by fast molecular docking.
Adesokan AA, Roberts VA, Lee KW, Lins RD, Briggs JM.
J Med Chem. 2004 Feb 12;47(4):821-8.
Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.
Chen X, Tsiang M, Yu F, Hung M, Jones GS, Zeynalzadegan A, Qi X, Jin H, Kim CU, Swaminathan S, Chen JM.
J Mol Biol. 2008 Jul 11;380(3):504-19. Epub 2008 May 1.
Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.
Kehlenbeck S, Betz U, Birkmann A, Fast B, Göller AH, Henninger K, Lowinger T, Marrero D, Paessens A, Paulsen D, Pevzner V, Schohe-Loop R, Tsujishita H, Welker R, Kreuter J, Rübsamen-Waigmann H, Dittmer F.
J Virol. 2006 Jul;80(14):6883-94.
Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain.
Molteni V, Greenwald J, Rhodes D, Hwang Y, Kwiatkowski W, Bushman FD, Siegel JS, Choe S.
Acta Crystallogr D Biol Crystallogr. 2001 Apr;57(Pt 4):536-44.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on